Preclinical studies have demonstrated that activated eosinophils can enhance anti-tumor responses through various mechanisms, including recruitment of tumor-specific CD8+ T cells, normalization of tumor vasculature, and modulation of tumor-associated macrophages [41]. This evidence concerns the gene CD8A and neoplasm.